The effects of the aromatase inhibitor fadrozole hydrochloride on fetuses and uteri in late pregnant rats

H Tamada, Y Shimizu, T Inaba, N Kawate and T Sawada

Laboratory of Theriogenology, Graduate School of Agriculture and Biological Sciences, Osaka Prefecture University, Sakai, Osaka 599-8531, Japan

Abstract

It is well known that progesterone and estrogen are essential hormones for maintaining pregnancy in most mammals. Some specific roles of progesterone for the maintenance of pregnancy have been clarified, but the role of estrogen is not well known. This study examines the effects of the aromatase inhibitor, fadrozole hydrochloride (Fad), on fetuses, uterine physical properties and the mRNA expression of the uterine enzymes that are related to collagen metabolism during late pregnancy in rats. Continuous s.c. infusion with 300 µg/day Fad from day 14 of pregnancy (day 1 = the day of sperm detection) reduced the concentration of plasma estradiol-17β (E2), and did not change that of plasma progesterone, compared with controls. The treatment increased the intrauterine pressure and reduced the size and compliance of the uterine tissue framework. It also caused injuries (hematomata on the extremities) in about one-quarter of fetuses by day 20. The collagen content of the uterine ampullae was not changed by the treatment. Uterine mRNA expressions of matrix metalloproteinase-1 (MMP-1), which degrades collagens, and of lysyl oxidase (LO), which is necessary for the formation of intra- and inter-molecular cross-links of collagen, were examined by quantitative RT-PCR. The treatment with Fad had no effect on the expression of MMP-1 mRNA and increased that of LO mRNA. Daily s.c. injection with 0.2 µg E2 restored the changes in uterine physical properties and the mRNA expression of LO caused by the Fad treatment, and prevented fetal injury, indicating that the influences of Fad treatment are due to estrogen deficiency but not to toxicological effects of Fad. These results imply that estrogen deficiency during late pregnancy in rats obstructs development of the uterine tissue framework so as to cause fetal injury. It is possible that an increase in the uterine expression of LO gene may be involved in this obstruction.


Introduction

The synergistic action of progesterone and estrogen is generally held to be essential for most mammals in maintaining fetuses during pregnancy (Courrier 1950). Progesterone is required for decidual growth (Deanesly 1973), and it inhibits the uterine contractions that expel fetuses (Fuchs 1978, Arkaravichien & Kendle 1992). Uterine immune function is reduced by progesterone-induced proteins secreted by the uterus (Zhang & Miller 1989, Liu & Hansen 1993), and together with estrogen, progesterone develops the uterine tissue framework so as to maintain low intrauterine pressure in the ovariectomized pregnant rat (Ichikawa & Tamada 1980, Tamada et al. 1984, 1989, 1990). Also, regulation of uterine blood flow by progesterone and estrogen (Ford et al. 1977) may be involved in the maintenance of pregnancy. Thus, some specific roles of progesterone for the maintenance of fetuses have been clarified, but the role of estrogen is relatively unknown.

Availability of an aromatase inhibitor of high specific activity, namely fadrozole hydrochloride (Fad), has enabled us to carry out experiments in which the production of estrogen is inhibited. This study examines the effects of continuous treatment with Fad, during late pregnancy, on the fetus and on physical properties of the uterus in rats. We also looked at the effect of Fad on mRNA expression of the uterine enzymes related to collagen metabolism, since changes in collagen metabolism might be related to the mechanism regulating the physical condition of the uterus.

Materials and Methods

Animals

All experiments were conducted in accordance with the Guidelines for Animal Welfare in Research and Education of Osaka Prefecture University. Sprague–Dawley rats bred in our laboratory were housed at 24 ± 1 °C with a ratio of...
14 h light:10 h darkness (lights on 0500–1900 h). The rats had free access to standard laboratory food (Rat-P; Nichiwa Mfg Co., Kobe, Japan) and tap water. Females were mated when they were 60–120 days old and had a body weight in the range 180–300 g. The day when spermatozoa were observed in the vaginal smear was designated day 1 of pregnancy. The pregnant rats were divided into three groups. At 1300–1400 h on day 1 of pregnancy the rats were implanted s.c. with mini-osmotic pumps (Model 2001; Alza Pharmaceuticals, Palo Alto, CA, USA) containing Fad (Fad group). Fad was released at the rate of 300 µg/day. Implantation was performed under ether anesthesia on the back, near the neck. Controls were implanted with a mini-osmotic pump containing vehicle (saline). The third group of rats underwent s.c. implantation of a mini-osmotic pump containing Fad, and received 0·2 µg estradiol-17β (E₂) daily after the implantation (Fad+E₂ group). E₂ was dissolved in 0·2 ml sesame oil and injected s.c. at 1400 h each day. At 1200–1400 h on day 17 of pregnancy, blood samples were collected from the abdominal aorta of rats in the control and Fad group, under ether anesthesia. The plasma was stored at −30 °C until the time of hormone assay. At 1000–1200 h on day 20 of pregnancy, the rats in all three groups underwent laparotomy under ether anesthesia, and the studies described below began. The rats were killed by an overdose of ether.

Hormone assays

The assays for progesterone, testosterone, androstenedione and E₂ were performed by enzyme immunoassay (EIA). Known amounts of the steroids were added to plasma obtained from ovariectomized–adrenalectomized rats, and standard curves were constructed. Progesterone was measured by the EIA method as described by Kawate et al. (1997). Commercial EIA kits were used for the assays of testosterone (Cayman Chemical, Ann Arbor, MI, USA), androstenedione (Oxford Biomedical Research, Inc., Oxford MI, USA) and E₂ (Cayman Chemical). The testosterone assay has been described previously (Kuwahara et al. 2000). For the androstenedione assay, steroid in the plasma was extracted by 10 volumes of diethyl ether. The extracts of samples (or standards), acetycholinesterase-labeled E₂ and antiserum were then mixed in the second antibody-coated wells, and were incubated at room temperature. The plate was then washed three times. Ellman’s reagent was then added to each well and the plate was incubated at room temperature, following which the absorbance was measured. The cross-reactivities of the anti-androstenedione antibody for androstenedione, estrone, pregnenolone, deoxycorticosterone, estrone-3-sulfate and E₂ were respectively 100, 1·5, 0·2, 0·1, 0·16 and 0·08%. Cross-reactivities of the anti-E₂ antibody for E₂, estrone, estriol, testosterone, 5α-dihydrotestosterone, estradiol-17α, androstenedione, androstenediol and progesterone were respectively 100, 7·5, 0·3, 0·1, 0·1, <0·01, <0·01, <0·01 and <0·01%. For each assay, all of the samples were quantified within a single assay. The intra-assay coefficient of variation and the lower limit of sensitivity were 8·7% and 156 pg/ml for progesterone, 11·7% and 3·9 pg/ml for testosterone, 7·9% and 125 pg/ml for androstenedione, and 9·7% and 3·9 pg/ml for E₂.

Determination of intrauterine pressure and classification of fetuses

The intrauterine pressure was determined for one to four amniotic cavities per rat using a pressure transducer (Nihon Kohden, Tokyo, Japan) immediately after laparotomy. The uterine wall, containing a live fetus, was pricked with a 20 G needle connected to the transducer through a polyethylene tube and the needle was placed in the amniotic cavity. To minimize the effect of the leakage of amniotic fluid through the needle prick on the next determination of intrauterine pressure, the fetuses not contiguous to the already determined ones were chosen for the following determinations. The signal from the transducer was amplified and recorded by a pen recorder. The mean values of the pressures were calculated for each rat.

After determination of the intrauterine pressure, the fetuses and placentae were removed and cleaned. The fetuses were divided into three groups, as reported previously (Tamada & Ichikawa 1980). Live normal fetuses were defined as those alive without visible signs of injury; injured fetuses were defined as live or recently dead fetuses bearing edematous hematoma; absorbing fetuses were those which were in the process of absorption, either with or without visible hematoma. The number of each category of fetus in each experimental group is expressed as a percentage of the total number of fetuses. The average weight of the live fetuses and their placentae were determined for each rat.
Determination of volume–pressure relationship in the uterine ampulla

The uterine ampulla in which a live fetus was included was removed, and the volume–pressure curve was determined as reported previously (Tamada et al. 1990). Briefly, the uterine ampulla was suspended in aerated Ca-free Tyrode’s solution containing 1·0 mM EGTA at 37 °C. A solution containing 0·1% pontamine sky blue, allowing any leak to be detected, was infused into the uterine ampulla at a rate of 1·0 ml/min, and the pressure and volume in the uterine ampulla during infusion were measured. Figure 1 shows a typical volume–pressure curve. Extrapolation of the linear middle part of the curve to zero pressure defines the intercept \( V_z \), which indicates the size of the uterine tissue framework at zero pressure; the slope \( \Delta V/\Delta P \) of the linear region was used as a measure of compliance. The conceptus, with its amniotic and allantoic sacs, was put into a graduated cylinder containing saline, and the increase in volume was measured.

Determination of collagen contents and quantitative analysis of matrix metalloproteinase-1 (MMP-1) and lysyl oxidase (LO) mRNA expression in the uterine ampulla

A uterine ampulla containing a live fetus was taken, and the conceptus was removed. The uterine tissue was cleaned and weighed and frozen immediately in liquid nitrogen. The tissue was stored at \(-80\) °C prior to the addition of the primer pairs for MMP-1 by seven cycles. The PCR conditions for MMP-1 were 2 min at 94 °C, 30 s at 58 °C, 30 s at 60 °C and 2 min at 72 °C. Expression of MMP-1 mRNA was weaker than that of RPL19 mRNA, and the proper expressions of both mRNAs were obtained in the same sample by delaying the addition of the primer pairs for MMP-1 by seven cycles. The PCR conditions for LO were 2 min at 94 °C for denaturation, followed by the specified number of cycles of 30 s at 94 °C, 30 s at 60 °C and 2 min at 72 °C. Expression of MMP-1 mRNA was weaker than that of RPL19 mRNA, and the proper expressions of both mRNAs were obtained in the same sample by delaying the addition of the primer pairs for LO by two cycles. After the PCR reaction, the products were immediately cooled to 4 °C, and 10 µl of the products were electrophoresed through a 1·5% agarose gel containing 0·5 µg/ml ethidium bromide. The resulting bands were examined with a UV transilluminator, and the relative densities were determined by densitometric scanning using the NIH-Image program (version 1·60; NIH, Bethesda, MD, USA). In quantitative RT-PCR, the densitometric intensities for the MMP-1 and LO were normalized to that of RPL19.
Effects of an aromatase inhibitor on fetuses and uteri

Table 1: Effects of Fad on plasma steroid concentrations in pregnant rats. The rats were given s.c. infusion with Fad or vehicle alone (control) from day 14 of pregnancy using a mini-osmotic pump, and steroid concentrations in plasma were determined on day 17. Values are means ± S.E.M.

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>No. of rats</th>
<th>E_2 (pg/ml)</th>
<th>Androstenedione (ng/ml)</th>
<th>Testosterone (ng/ml)</th>
<th>Progesterone (ng/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>5</td>
<td>29.6 ± 5.3</td>
<td>8.6 ± 1.5</td>
<td>1.2 ± 0.3</td>
<td>85.2 ± 9.4</td>
</tr>
<tr>
<td>Fad</td>
<td>5</td>
<td>15.7 ± 1.5^a</td>
<td>15.6 ± 1.1^b</td>
<td>2.5 ± 0.2^b</td>
<td>79.4 ± 6.7</td>
</tr>
</tbody>
</table>

Notes: ^aP<0.05 vs controls. ^bP<0.01 vs controls.

Results

Effect of Fad on the plasma steroid concentrations

Table 1 shows the plasma steroid concentrations in the Fad group and the controls on day 17 of pregnancy. The E_2 concentration was significantly lower in the Fad group than in the controls. Androstenedione and testosterone concentrations were higher in the Fad group than in the controls, however. The progesterone level did not differ between the groups.

Effect of Fad on the intrauterine pressure and fetuses

Table 2 shows the effects of Fad on the intrauterine pressure and the fetuses on day 20 of pregnancy. The intrauterine pressure in the Fad group was about four times higher than in the controls. The pressure in the Fad+E_2 group did not differ from that in controls.

Macroscopically, constriction rings between the uterine ampullae were observed in the Fad group. The constriction rings were not found in the controls or the Fad+E_2 group, however. Although no abnormality was found in any live fetuses in the control and the Fad+E_2 group, all rats in the Fad group were carrying injured fetuses, with edematous hematoma on their extremities as shown in Fig. 2. In total, over 20% of fetuses had injuries on their head or clunis (Table 2). Weights (means ± S.E.M.) of live fetuses and their placentae were 2.18 ± 0.05 and 0.45 ± 0.02 g in the controls, 2.29 ± 0.07 and 0.43 ± 0.01 g in the Fad group, and 2.33 ± 0.07 and 0.47 ± 0.03 g in the Fad+E_2 group. There were no statistically significant differences between these values among the groups.

Effect of Fad on the size and compliance of uterine tissue framework

Table 3 shows the effects of Fad on the volume of the conceptus and the size and compliance of the uterine tissue framework. There were no significant differences between the volumes of conceptus among the groups.

Analysis of RT-PCR products

The PCR product for MMP-1 was analyzed using the restriction enzyme DraI (New England Biolabs, Inc., Beverly, MA, USA). DraI was added to the product at a concentration of 1.64 U/µl, and the mixture was incubated for 1 h at 37°C. The reaction mixture was electrophoresed through a 2% agarose gel containing ethidium bromide. The resulting bands were examined with a UV transilluminator.

The bands of the PCR products for LO in the gel were dissected out on a UV transilluminator, and cDNAs were extracted using a QIAEX II Gel Extraction Kit (Qiagen, Hilden, Germany). By using a TA cloning Kit (Invitrogen, Carlsbad, CA, USA), the purified cDNAs were subcloned into the pCRII plasmid vector, and transformed into INVαF’ chemically competent Escherichia coli. The cDNAs in the bacteria were isolated from bacterial solutions originating from three colonies, using a Qiagen Plasmid Mini Kit.

Sequences were generated in both directions, using an ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems, Branchburg, NJ, USA). Sequencing reactions were analyzed on an ABI Prism 310 Genetic Analyzer (Perkin Elmer, Norwalk, CT, USA). The results were compared using the Genetyx-Mac Version 8/0 software (Software Development, Tokyo, Japan).

Statistics

Values are expressed as means with S.E.M. Steroid concentrations were evaluated using Student’s t-test, and the difference between mean values with unequal variances was analyzed by Welch’s modified t-test. The intrauterine pressure, fetal and placental weights, volume of conceptus, V_e, compliance, collagen content in the uterine ampulla and relative mRNA expressions were analyzed using ANOVA, followed by Fisher’s protected least-significant difference post-hoc analysis. Thresholds used to apply the significant difference were 5 or 1%. The Stat View computer program (Hulinks Inc., Tokyo, Japan) was employed.
The uterine tissue framework at zero pressure, \(V_z\), was significantly smaller in the Fad group than in the control or Fad+E2 groups. Although the values of \(V_z\) in the control and Fad+E2 groups were larger than the volume of the conceptus, the value in the Fad group was considerably smaller than the conceptus volume. The compliance was significantly smaller in the Fad group than in the control or Fad+E2 groups.

### Effects of Fad on collagen content and expression of MMP-1 and LO mRNA in the uterus

The collagen content (means ± S.E.M.) in a uterine ampulla was 7.98 ± 0.97 mg in the controls (\(n=5\)), 7.82 ± 0.32 mg in the Fad group (\(n=5\)), and 7.96 ± 0.27 mg in the Fad+E2 group (\(n=6\)). The values did not differ among the groups.

Bands of the expected sizes (360 bp for MMP-1, 338 bp for LO and 195 bp for RPL19) were found in the RT-PCR. A negative control for the PCR reaction, in which the reverse transcriptase was omitted, yielded no PCR bands for any of the target mRNAs (not shown).

Using 1 \(\mu\)g total RNA, the relationship between cycle number and densitometric intensity of the RT-PCR product for MMP-1 or RPL19 was examined. The densitometric intensity of the band for MMP-1 was linear between 31 and 35 cycles, and for RPL19 (determined at the same time) was linear between 22 and 28 cycles. The quantitative RT-PCR assay was therefore performed at 34 cycles for MMP-1 and at 27 cycles for RPL19. Figure 3A shows the linear response of RT-PCR for MMP-1 and RPL19 vs the concentration of total RNA used for RT; the assay was not linear beyond 500 ng RNA. A further

---

**Table 2** Effects of Fad on intrauterine pressure and fetal injury in pregnant rats. The rats were given s.c. infusion with Fad or vehicle alone (control) from day 14 of pregnancy using a mini-osmotic pump. Daily s.c. injection of E2 took place from day 14 through to day 19. The intrauterine pressure was determined on day 20. Values are means ± S.E.M.

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>No. of rats</th>
<th>Intrauterine pressure (mmHg)</th>
<th>Fetuses</th>
<th>Total no.</th>
<th>Live normal (%)</th>
<th>Injured (%)</th>
<th>Absorbing (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>7</td>
<td>4.6 ± 0.5</td>
<td>84</td>
<td>92.9</td>
<td>0</td>
<td>7.1</td>
<td></td>
</tr>
<tr>
<td>Fad</td>
<td>6</td>
<td>16.8 ± 1.5*</td>
<td>84</td>
<td>56.0</td>
<td>22.6</td>
<td>21.4</td>
<td></td>
</tr>
<tr>
<td>Fad+E2</td>
<td>9</td>
<td>5.1 ± 0.3</td>
<td>108</td>
<td>99.1</td>
<td>0</td>
<td>0.9</td>
<td></td>
</tr>
</tbody>
</table>

*P < 0.01 vs controls or Fad+E2 group.

---

**Figure 2** Fetuses on day 20 of pregnancy in a rat treated with Fad, showing a normal live fetus (left) and an injured live fetus bearing a hematoma on the head (right). The mother was given s.c. infusion with Fad from day 14 of pregnancy using a mini-osmotic pump. All fetuses in the vehicle-treated controls and Fad+E2-treated rats were normal.
assay was performed using 350 ng RNA. Figure 3B shows that the expressions of MMP-1 mRNA were not different among the three groups.

Using 1µg total RNA, the relationship between cycle number and densitometric intensity of the RT-PCR product for LO or RPL19 was examined. The intensity for LO was linear between 20 and 26 cycles, and for RPL19 (determined at the same time) was linear between 22 and 25 cycles. The quantitative RT-PCR assay was therefore performed at 25 cycles for LO and at 23 cycles for RPL19. Figure 4A shows the linear response of RT-PCR for LO and RPL19 vs the concentration of total RNA used for RT; the assay was not linear beyond 62.5–125 ng RNA. A further assay was performed using 62.5 ng RNA.

**Table 3** Effects of Fad on volume of the conceptus and size and compliance of uterine tissue framework in pregnant rats. The rats were given s.c. infusion with Fad or vehicle alone (control) from day 14 of pregnancy using a mini-osmotic pump. Daily s.c. injection of E2 took place from day 14 through to day 19. Values were determined on day 20, and are shown as means ± S.E.M.

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>No. of samples measured</th>
<th>Volume of conceptus (ml)</th>
<th>Uterine tissue framework</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Size at zero pressure, V₀ (ml)</td>
</tr>
<tr>
<td>Control</td>
<td>10</td>
<td>3.67 ± 0.14</td>
<td>4.92 ± 0.20</td>
</tr>
<tr>
<td>Fad</td>
<td>8</td>
<td>4.00 ± 0.0</td>
<td>2.66 ± 0.22⁻ᵇ</td>
</tr>
<tr>
<td>Fad+E₂</td>
<td>9</td>
<td>3.72 ± 0.12</td>
<td>4.52 ± 0.17</td>
</tr>
</tbody>
</table>

*See Fig. 1 for definition of the values.
⁻ᵇP<0.01 vs controls or Fad+E₂ group.

**Figure 3** Quantitative RT-PCR assay of MMP-1 and RPL19 transcripts in the uterus of pregnant rats. Total RNA was isolated from the uterine ampulla on day 20 of pregnancy. To obtain proper expressions of both transcripts, addition of the primer pairs for MMP-1 was delayed by seven cycles, and the assay was performed at 34 cycles for MMP-1 and 27 cycles for RPL19. (A) Representative photographic record, and arbitrary densitometric units (ADUs) of the RT-PCR product of MMP-1 and RPL19 shown as a function of the total RNA. (B) Uterine expression of MMP-1 mRNA in controls, Fad-treated rats and Fad+E₂-treated rats are shown in the representative photographic records and as relative values of densitometric units of MMP-1 against that for RPL19 of the RT-PCR products. The rats were given s.c. infusion with Fad or vehicle alone (control) from day 14 of pregnancy using a mini-osmotic pump. Daily s.c. injection with E₂ took place from day 14 through day 19. The assay was performed using 350 ng total RNA. Similar results were obtained when the assay was repeated, and mean values for each sample were taken. Values are means ± S.E.M. (n=5); there were no significant differences among groups.
Figure 4B shows the expression of LO mRNA in the Fad group was higher than in the control and Fad+E2 groups.

Analysis of RT-PCR products

The RT-PCR product for MMP-1 was cut into two fragments of the expected sizes (238 and 122 bp) by the restriction enzyme DraI (not shown). The cDNA sequence of the RT-PCR product for LO was in complete correspondence with the cDNA sequence for LO mRNA reported by Trackman et al. (1990).

Discussion

Although progesterone and estrogen are both hormones required for maintaining pregnancy (Courrier 1950), the role of estrogen is not fully known. To study the specific roles of estrogen during the second half of pregnancy, the effects were examined of a non-steroidal aromatase inhibitor of high specific activity, Fad, on the fetuses and uterus in rats. Continuous s.c. infusion of Fad is reported to cause delay of implantation (Tamada et al. 2003) and to be effective in inhibiting estrogen production in rats (Selvaraj et al. 1994, Shetty et al. 1995), so sufficient Fad to inhibit estrogen production was administered using a mini-osmotic pump from day 14 of pregnancy. This Fad treatment reduced the plasma E2 concentration and increased levels of androstenedione and testosterone, suggesting that the treatment effectively inhibited aromatase activity. The Fad treatment had no effect on plasma progesterone concentration, however. It has been reported that estrogen stimulates luteal progesterone synthesis (Gibori et al. 1984), and that androstenedione also stimulates progesterone production (Goyeneche et al. 2002). Inhibition of luteal progesterone synthesis due to estrogen deficiency might be overcome by the stimulating effect of the increased androstenedione level.

We have reported that in ovariectomized pregnant rats, progesterone together with estrogen develops the uterine tissue framework to maintain low intrauterine pressure (Ichikawa & Tamada 1980, Tamada et al. 1984, 1989, 1990). Estrogen deficiency following Fad treatment consistently caused a 4-fold increase in the intrauterine pressure. The uterine constriction rings remained on day 20 of pregnancy. Fetal elongation takes place when the...
intrauterine pressure forces the edges of the amniotic sac into the inter-conceptus rings of the uterine wall, gradually eliminating the constriction rings between the uterine ampullae (Tamada & Ichikawa 1980). The hematoma observed on the head or clunis of the fetuses in the Fad group might be caused by the extremities of the growing fetuses being pressed onto the constriction rings under abnormally high pressure. To study the physical properties of the uterine tissue framework, the volume–pressure relationship was determined in Ca-free Tyrode’s solution containing EGTA, which eliminates uterine contractile activity. The size of the uterine tissue framework at zero pressure, \( V_0 \), was markedly smaller in the Fad group than the volume of the conceptus, suggesting that the conceptuses do consistently suffer from uterine pressure. In the controls, by contrast, \( V_0 \) was greater than the volume of conceptuses. Furthermore, Fad treatment reduced the compliance of the uterine tissue framework. Since treatment with \( E_2 \) restored the changes in uterine physical properties caused by the Fad treatment and prevented fetal injuries, it is possible that the specific role of estrogen in the second half of pregnancy is to develop the uterine tissue framework needed to maintain normal fetal growth in rats. The importance of the uterine physical environment to fetal survival during late pregnancy has been demonstrated in ovariectomized rats and rats treated with a progesterone antagonist (Tamada & Mori 1995, Tamada et al. 1998). Although high doses of androgens have estrogenic effects and maintain successful pregnancy in the ovariectomized progesterone-treated rats (Hosoda et al. 1984), increased production of androgen in the Fad-treated rats could not have overcame the influences of the estrogen deficiency.

Reticular and collagenous fibers, which consist of bundles of collagen fibrils, extend into extracellular spaces in the uterine smooth muscles to make a network of fibers (Bloom & Fawcett 1975). Since collagen is mechanically very strong in the soft tissue materials, it is likely to be the main determinant of the physical properties of the uterine tissue framework, as proposed by Cullen & Harkness (1964). The effects of estrogen on uterine collagen metabolism have been studied. Ryan & Woessner (1972) showed that administration of \( E_2 \) to parturient rats strongly inhibits the loss of collagen from the involuting uterus, and found that this effect is due to inhibition of collagen degradation rather than stimulation of collagen synthesis. Furthermore, Woessner (1979) found that injection with \( E_2 \) causes a decrease in uterine collagenase activity that is correlated with the rate of collagen breakdown. Frankel et al. (1988) found that \( E_2 \) induces \( \alpha_1 \) (I) and \( \alpha_2 \) (III) collagen mRNAs in the immature rat uterus, and Dyer et al. (1980) reported that \( E_2 \) stimulates both synthesis and degradation of collagen in the ovariectomized rat uterus. It therefore seems that the effect of estrogen on collagen metabolism in the uterus changes according to the physiological state of the animals. Here, during the second half of pregnancy Fad treatment did not affect the collagen content or the mRNA expression of a representative collagenase, MMP-1, in the uterine ampulla. These observations suggest that estrogen deficiency does not have significant effects on either the synthesis or degradation of uterine collagen. Progesterone is reported to retard loss of collagen in the involuting post-partum rat uterus (Halme & Woessner 1975) and to inhibit the production of collagenase in rat myometrial smooth muscle cells in culture (Jeffrey et al. 1990). During pregnancy, a high level of progesterone might strongly inhibit collagenase production to nullify the influence of estrogen, so maintaining the low constant level of uterine MMP-1 mRNA expression.

LO initiates covalent cross-linking between and within the molecular units of collagen and of elastin by oxidizing peptidyl lysine in these proteins to peptidyl \( \alpha \)-aminoadipic-\( \delta \)-semialdehyde. The peptidyl aldehyde can then condense with neighboring amino groups or peptidyl aldehydes to form the covalent cross-linkages found in fibrillar collagen and elastin (Kagan 1986). Patients with cutis laxa, which is characterized by hyper-extensible skin, have a deficiency of LO (Kagan 1986, Khakoo et al. 1997). It is therefore possible that the level of uterine expression of LO is closely related to uterine physical properties. The present study has examined for the first time the effect of \( E_2 \) on uterine expression of LO mRNA, and found that estrogen deficiency during pregnancy increases its expression in the rat. The increased LO mRNA expression might have inhibited development of the uterine tissue framework, causing the smaller size and compliance of the uterine tissue framework in the Fad-treated rats.

In conclusion, this study has shown that estrogen deficiency in rats during late pregnancy obstructs the development of the uterine tissue framework that is required for uterine accommodation of the rapidly growing fetuses. As a result, the fetuses are pressed by abnormally high intrauterine pressure and suffer from hematoma on the head or clunis. A high level of uterine expression of the LO gene may be involved in obstructing the development of the uterine tissue framework.

Acknowledgement

The authors gratefully thank Novartis Pharma (Tokyo, Japan) for the donation of CGS 16949A (fadrozole hydrochloride).

Funding

This work was supported in part by a Grant-in-Aid for Scientific Research (C) (2) No. 14560269 from the Japan Society for the Promotion of Science. There are no conflicts of interest or potential conflicts of interest.